OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
OptimizeRx CorporationNASDAQ: OPRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $495K (cash outflow) fell 77.5% year over year, behind the +144.4% change in trailing-twelve-month net income.
Context
- Net income amounted to 4.7% of revenue in FY2025, down 17.1 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $16.31M (+217.7%) for the fiscal year ending Dec 2026, a step up from the +125.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$495K-109.9% QoQ
- Last fiscal yearDec 2025
- $5.13M+125.5% YoY
- LTMMar 2026
- $6.84M+144.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.5% | +39.4% | +116.9 pp |
| 1 year | +125.5% | +217.7% | +92.2 pp |
| 3-year CAGR | — | +57.3% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 5.13M USD
- Year-over-year change
- +125.5%
- 4-year CAGR
- +91.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.13M | +125.5% |
| FY2024 | 2024-12-31 | (20.11M) | -14.5% |
| FY2023 | 2023-12-31 | (17.57M) | -53.6% |
| FY2022 | 2022-12-31 | (11.44M) | -3125.4% |
| FY2021 | 2021-12-31 | 378.08K | — |
Net Income vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +144.4% is the 4th highest of 10, against a peer median of +23.8%.
- Net income amounts to 6.4% of revenue for OPRX, versus a peer median of 56.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $289.97M USD | +6530.4% | +173.9% | 7397.8% | |
| LTM Mar 2026 | $182.83M USD | -71.5% | +107.7% | 76.7% | |
| LTM Mar 2026 | $80.17M USD | +23.8% | -3.4% | 98.8% | |
| LTM Feb 2026 | $62.79M USD | -964.8% | — | 78.0% | |
| LTM Mar 2026 | $46.64M USD | +75.7% | -16.4% | 36.6% | |
| LTM Mar 2026 | CA$27.53M CAD | +699.2% | -6.5% | — | |
| LTM Mar 2026 | $16.51M USD | +191.1% | -35.0% | 4.8% | |
| LTM Mar 2026 | $12.67M USD | -20.4% | -10.1% | 9.3% | |
| LTM Mar 2026 | $9.04M USD | -62.7% | -28.5% | 6.5% | |
| LTM Mar 2026 | $6.84M USD | +144.4% | — | 6.4% | |
| Peer median (excluding OPRX) | — | +23.8% | -8.3% | 56.7% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| Deferred Income Tax | 0 | 0 | 0 | 1.45M | 1.21M |
| Stock-Based Compensation | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M |
| Change in Working Capital | (7.19M) | 3.96M | (15.55M) | 921K | 816K |
| Accounts Receivables | (6.99M) | 2.28M | (8.71M) | (2.17M) | 460K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (603.09K) | 555.4K | 195K | (72K) | (520K) |
| Other Working Capital | 408.65K | 1.12M | (7.03M) | 3.16M | 876K |
| Other Non-Cash Items | 80K | 363.51K | 9.76M | 6.83M | 264K |
| Operating Cash Flow | 726.04K | 10.65M | (7.24M) | 4.89M | 18.72M |
| Capital Expenditures | (486K) | (244.57K) | (871K) | (112K) | (58K) |
| Acquisitions (Net) | 0 | (2M) | (80.41M) | 0 | 0 |
| Purchases of Investments | 0 | (55.93M) | (162.78M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 218.71M | 0 | 0 |
| Other Investing Activities | (385.68K) | (163.56K) | (774K) | (338K) | 126K |
| Investing Cash Flow | (486K) | (58.18M) | (25.34M) | (450K) | 68K |
| Debt Repayment | 0 | 0 | 36.02M | (4M) | (8M) |
| Common Stock Issued | 70.67M | 0 | 0 | 0 | 352K |
| Common Stock Repurchased | 0 | (20.02M) | (7.52M) | (911K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.25M | 1.07M | (278K) | 0 | (1.15M) |
| Financing Cash Flow | 73.92M | (18.95M) | 28.22M | (4.91M) | (8.8M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.16M | (66.47M) | (4.36M) | (472K) | 9.99M |
| Free Cash Flow | 240.04K | 10.41M | (8.11M) | 4.78M | 18.66M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.